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Familial hypertrophic cardiomyopathy (HCM), due to point mutations in genes for
sarcomere proteins such as myosin, occurs in 1/500 people and is the most common
cause of sudden death in young individuals. Similar mutations in skeletal muscle, e.g.,
in the MYH7 gene for slow myosin found in both the cardiac ventricle and slow skeletal
muscle, may also cause severe disease but the severity and the morphological changes
are often different. In HCM, the modified protein function leads, over years to decades,
to secondary remodeling with substantial morphological changes, such as hypertrophy,
myofibrillar disarray, and extensive fibrosis associated with severe functional deterioration.
Despite intense studies, it is unclear how the moderate mutation-induced changes in
protein function cause the long-term effects. In hypertrophy of the heart due to pressure
overload (e.g., hypertension), mechanical stress in the myocyte is believed to be major
initiating stimulus for activation of relevant cell signaling cascades. Here it is considered
how expression of mutated proteins, such as myosin or regulatory proteins, could have
similar consequences through one or both of the following mechanisms: (1) contractile
instabilities within each sarcomere (with more than one stable velocity for a given load),
(2) different tension generating capacities of cells in series. These mechanisms would have
the potential to cause increased tension and/or stretch of certain cells during parts of the
cardiac cycle. Modeling studies are used to illustrate these ideas and experimental tests
are proposed. The applicability of similar ideas to skeletal muscle is also postulated, and
differences between heart and skeletal muscle are discussed.
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INTRODUCTION
Hereditary heart diseases, cardiomyopathies, with mutations in
genes for key proteins in the muscle sarcomere (Figure 1) occur
in as many as 1/500 people and are the most common cause of
sudden death in young individuals (Harvey and Leinwand, 2011;
Teekakirikul et al., 2012). Some of the most commonly affected
proteins include ventricular β-myosin heavy chains, myosin bind-
ing protein C, troponin I, troponin T, tropomyosin, and myosin
regulatory light chains (Xu et al., 2010).While much attention has
been directed to sarcomere myopathies in the heart, the insight
into their genetic basis (Geisterfer-Lowrance et al., 1990) trig-
gered interest into related skeletal muscle diseases (Cuda et al.,
1993; Martinsson et al., 2000). The consequences of these skeletal
muscle sarcomere myopathies may be equally severe with, grave
disability, respiratory failure and death at a young age (Laing
and Nowak, 2005b; Laing, 2007; Ochala, 2008; Tajsharghi and
Oldfors, 2013). Interestingly, however, a large majority of the
myosin mutations that cause severe cardiomyopathy, only cause
mild skeletal muscle disease (Oldfors, 2007). Severe disease in
skeletal muscle is generally associated with mutations in thin fila-
ment proteins such as nebulin (not present in heart), actin, or the
regulatory troponin-tropomyosin complex (Ochala, 2008).
Importantly, both in heart and skeletal muscle, severe disease
often does not develop until adolescence or adulthood (Frey et al.,
2012). This offers a time window that should be useful for ther-
apeutic interventions. However, such options are currently ham-
pered by lack of insight into the mechanisms whereby the minor,
primary disturbances in the sarcomere proteins are transformed
into disease with appreciable morphological changes (Laing and
Nowak, 2005a; Ochala, 2008; Frey et al., 2012; Teekakirikul et al.,
2012). In the heart there is, for instance, severe hypertrophy
with increased wall thickness and cell volume (hypertrophic
cardiomyopathy-HCM) or dilation with elongated cells and larger
ventricular cavities (dilated cardiomyopathy-DCM). The changes
in HCM are associated with myofibrillar disarray and fibrosis
throughout the myocardium (Ashrafian et al., 2011; Frey et al.,
2012; Teekakirikul et al., 2012) but also with microvascular dis-
ease and defects in the mitral valves (Ashrafian et al., 2011). In
skeletal muscle, the picture in myopathies is diverse both clin-
ically and morphologically (Laing and Nowak, 2005a; Oldfors,
2007; Ochala, 2008; Marston et al., 2013; Tajsharghi and Oldfors,
2013). Here, the focus will be primarily on hereditary HCM
due to appreciably higher prevalence than hereditary DCM. The
developed ideas will also be considered in relation to hereditary
skeletal muscle diseases with mutations in sarcomeric proteins.
It is important to note that the term “HCM” will only refer to
hereditary disease. It is not used to denote acquired diseases asso-
ciated with cardiac hypertrophy, for example in pressure overload.
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FIGURE 1 | The sarcomere, the highly ordered functional unit of
striated muscle with key protein components schematically
illustrated. The resting length of the sarcomere is approximately 2.0μm in
the human heart and 2.5μm in human skeletal muscle.
One major reason why the mechanisms underlying HCM
and skeletal muscle myopathies remain elusive is the apprecia-
ble multidimensional complexity in spite of a simple primary
defect in the form of a point mutation. First of all, the time
dependent secondary changes most likely start already during
embryonic development (Olivotto et al., 2009). These changes
continue throughout life, while being modulated by a range of
environmental, genetic and epigenetic factors that may mod-
ify disease penetrance and where each is likely to vary with
time (Cooper et al., 2013). This time dependence and vari-
ability in clinical course has contributed to the difficulty of
obtaining a clear and comprehensive picture of the patho-
genesis even for a given point mutation. The picture is fur-
ther blurred by the additional dimension that the path from
a given isolated mutation to full-blown disease seems to vary
between humans and typical experimental animals, e.g., trans-
genic mice (Lowey et al., 2008, 2013; Spudich, 2014). Adding
further to the complexity, recent studies have also suggested
that the proportional expression of wild-type and mutated pro-
tein may vary between cells in the same individual (Kirschner
et al., 2005), and that there is allelic imbalances with differ-
ent proportional expression of the mutated protein in differ-
ent heterozygous individuals (Casadonte et al., 2006; Tripathi
et al., 2011; Di Domenico et al., 2012). Considering all the
above, it is not surprising that it is highly challenging to arrive
at a clear understanding of the pathogenesis of the sarcomere
myopathies. Indeed, there are even conflicting views on how a
given myosin mutation affects the actomyosin cross-bridge func-
tion and whether it leads to gain or loss of function (Wang
et al., 2003; Lowey et al., 2008, 2013; Sommese et al., 2013b)
(reviewed by Spudich, 2014). Part of the reason for the discrep-
ancies seems to be that a given myosin mutation has different
effects depending on the myosin isoform background, a prop-
erty that varies between species due to differences in dominant
ventricular isoform (Lowey et al., 2008, 2013). Recent insights
gained using expression of wild-type and mutated proteins from
both humans and key experimental animals seem to suggest
that there is a tendency (Kohler et al., 2003; Marston, 2011;
Teekakirikul et al., 2012; Bai et al., 2013; Spudich, 2014), although
with exceptions (Greenberg et al., 2010), for HCM mutations in
myosin and regulatory proteins to cause increased rather than
reduced power output and/or increased rather than reduced
Ca-sensitivity. There is also some evidence for early hypercon-
tractility on the whole organ level (Teekakirikul et al., 2012)
although the evidence is not unequivocal (Witjas-Paalberends
et al., 2013). The association between increased diastolic pres-
sure (related to, so called, diastolic heart failure) in HCM and
an increased Ca-sensitivity (Ferrantini et al., 2009; Ashrafian
et al., 2011; Harvey and Leinwand, 2011; Marston, 2011; Frey
et al., 2012; Lovelock et al., 2012; Teekakirikul et al., 2012; Bai
et al., 2013; Memo and Marston, 2013; Witjas-Paalberends et al.,
2013; Sommese et al., 2013a; Spudich, 2014) seems to have
gained more general, although not universal (Kirschner et al.,
2005), acceptance. However, in this connection it should be men-
tioned that diastolic dysfunction can also be caused by changes
in titin function. This has been demonstrated in mouse models
where shortening of the titin spring region (Chung et al., 2013)
caused increased ventricular wall stiffness. Moreover, in clinical
studies (Borbely et al., 2009) hypophosphorylation of a specific
titin isoform increased resting tension with possible implications
for diastolic dysfunction in cardiomyocytes from failing human
myocardioum.
A majority of the secondary remodeling effects in heredi-
tary HCM are reminiscent of those in pressure overload such as
caused by hypertension and aortic stenosis. This includes hyper-
trophy and fibrosis as well as changes in gene expression profile
to a more fetal pattern (cf. Bernardo et al., 2010; Harvey and
Leinwand, 2011). A difference is the often more patchy and
regional appearance of the secondary changes in HCM due to sar-
comeric protein mutation. In cardiac hypertrophy due to pressure
overload, mechanical stimuli affecting the myocytes are believed
to be major initiators of changes in cell signaling that lead to
hypertrophy (Bernardo et al., 2010).
An important question that remains to be answered is why
similar signaling pathways as in pressure overload would be acti-
vated in HCM (Ferrantini et al., 2009; Olivotto et al., 2009;
Ashrafian et al., 2011; Harvey and Leinwand, 2011; Frey et al.,
2012; Moore et al., 2012; Teekakirikul et al., 2012). Here, I
hypothesize that the initiating stimuli in HCM are similar as in
pressure overload but more localized, i.e., they involve increased
mechanical stress that only affects a limited fraction of the car-
diomyocytes. I further use model studies for initial tests as to
whether this hypothesis is consistent with either or both of
the following ideas: (i) that altered kinetics of the actomyosin
interaction causes critical instabilities in the force-velocity (F-
V) relation at the sarcomere level (Julicher and Prost, 1995;
Vilfan et al., 1999; Mansson, 2010) and/or (ii) that certain cells
in the heart or segments of skeletal muscle fibers are stretched
during overall isometric/isovolumetric contraction due to non-
uniformity in force-generating capacity between cells (Kirschner
et al., 2005).
CELL SIGNALING AND PHENOTYPE IN PRESSURE
OVERLOAD AND IN HCM—SIMILARITIES AND DIFFERENCES
Stimulation of angiotensin II (AT-II) receptors appears to be
central in the signaling pathways that lead to hypertrophy, fibro-
sis etc. in HCM, as well as in pressure overload and, at least
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in, pressure overload, it seems clear that this signaling is initi-
ated by mechanical stress (Lijnen and Petrov, 1999; Lim et al.,
2001; Amedeo Modesti et al., 2002; Zou et al., 2004; Bernardo
et al., 2010; Ashrafian et al., 2011; Harvey and Leinwand, 2011;
Weeks and McMullen, 2011; Teekakirikul et al., 2012; Luo et al.,
2013). The down-stream effects are enhanced or complemented
by the action of noradrenaline and endothelin on other G-
protein coupled receptors and possibly by paracrine substances
released from non-cardiomyocyte cells (Teekakirikul et al., 2012;
Cilvik et al., 2013). These effects involve calcium dependent cal-
cium/calmodulin kinase and calcineurin as well as a range of
transcription factors ultimately leading tomarked changes in pro-
tein expression (Bernardo et al., 2010; Harvey and Leinwand,
2011). Importantly, these pathologic pathways largely differ from
those in physiologic hypertrophy (“athletes heart”) which seem to
mainly involve activation of the Akt-mTOR pathway (Bernardo
et al., 2010; Weeks and McMullen, 2011).
The similarities in phenotype (hypertrophy associated with
fibrosis and similar changes in protein expression pattern)
between HCM and pressure overload as well as the involvement
of similar signaling systems in the two cases seems undisputed
on the basis of a survey of the literature. However, whereas the
mechanical stimulus that initiates such signaling seems quite
straightforward in pressure overload the initiating mechanism is
less evident in HCM. It has been suggested that reduced energy
efficiency of contraction is of importance in this regard but it is
not clear how (Jung et al., 1998; Sweeney et al., 1998; Crilley et al.,
2003; Frey et al., 2006; Luedde et al., 2009; Harvey and Leinwand,
2011; Marston, 2011; Frey et al., 2012; Teekakirikul et al., 2012).
Another possibility that has also been widely considered is that
disturbances in Ca-homeostasis, as a result of the mutations,
could be a triggering factor (Ferrantini et al., 2009; Ashrafian
et al., 2011; Harvey and Leinwand, 2011; Marston, 2011; Frey
et al., 2012; Teekakirikul et al., 2012). The latter disturbances may
be secondary to inefficient energy usage which may reduce cal-
cium pumping by the sarcoplasmic reticulum ATPase. They may
also be understood more directly for mutations that alter the Ca-
affinity of troponin (Marston, 2011) thereby not only affecting
the Ca-sensitivity of contraction but also changing the calcium
buffering capacity.
STATEMENT OF HYPOTHESIS
I propose here an alternative hypothesis with the aims of supple-
menting existing ideas (cf. above) and stimulating new experi-
ments and modeling studies. To the best of my knowledge this
hypothesis has not been considered previously, at least not explic-
itly, but it has been stimulated by recent findings (Kirschner et al.,
2005; Mansson, 2010) (see below for details).
I hypothesize that in HCM: (1) similar signaling pathways
(associated with AT-II) operate as in pressure overload, but less
homogeneously over the ventricular wall and (2) that the dom-
inant initiating stimulus that activates these pathways is similar
to that in pressure overload, i.e., increased cellular stress/stretch.
The major distinguishing feature, compared to pressure over-
load, is the idea that the mechanical effects act locally on sub-
populations of the cells, rather than globally on all ventricular
cells.
INITIATION OF PATHOLOGIC SIGNAL TRANSDUCTION IN
HCM
Two mechanisms are considered (see sub-sections below) that
may mediate mechanical initiation of pathologic signal transduc-
tion. Themajor components of the overall hypothesis and the two
mechanisms are summarized in Figure 2. The possible relation
to skeletal muscle myopathies is discussed in a separate section
at the end of the paper but is also considered briefly in other
sections.
INSTABILITY ON SARCOMERE LEVEL
Model studies (Julicher and Prost, 1995; Vilfan and Frey, 2005;
Mansson, 2010) have suggested that certain combinations of
parameter values that govern the actomyosin interactions may
produce mechanical instabilities. These are characterized by
anomalous load-velocity (F-V) relationships of the muscle with
more than one stable velocity for a given load. This is illustrated
in Figure 3 for a model similar to that in (Mansson, 2010). Here,
the black curve simulates a “normal” F-V relationship based on
the parameter values in Table S1 whereas the red curve simulates
a relationship with instability at loads close to the isometric (see
below and legend of Figure 3 for details).
As pointed out previously (Mansson, 2010), regions of posi-
tive or infinite derivative of velocity with respect to force dV/dF
(Figure 3) may be deleterious for normal muscle function with
unpredictable effects and potential difficulties of regulation. The
effect may be critical if sarcomeric units in series have different
force-generating capacity. This is observed physiologically (see
below) and it is proposed here, that the phenomenon is enhanced
in myopathies.
The normally low magnitude of the negative slope |dV/dF|
of the F-V relationship for lengthening and in the high-force
region for shortening is probably important in order to reduce
sarcomere-length redistribution during contractions where iso-
metric or almost isometric tension is developed (Edman et al.,
1997). This stabilizing effect follows from appreciable drop in
tension-generating capability with a small increase in shortening
velocity of the strongest fiber segments (the ones that shorten)
and a high increase in resistance to stretch of elongating segments.
Without such an inherent stabilization, the weakest segments
may become severely overstretched with potential damage to the
cell or strong local stimulation of hypertrophic signaling. The
latter would be expected because stretch of a weak cell during
activity will cause stretch of titin in this cell as well as high ten-
sion in the individual filaments and Z-lines, structures known
to be associated with tension-, and strain-sensing (Luther, 2009;
Linke and Kruger, 2010; Ottenheijm et al., 2011; Raskin et al.,
2012).
A recently reported loss of the Frank-Starling mechanism in
HCM (Sequeira et al., 2013) may also contribute to sarcomere
instability similar to that seen with an anomalous F-V rela-
tionship. Thus, in normal cardiac muscle, the Frank-Starling
mechanism immediately (Mateja and De Tombe, 2012) increases
Ca-sensitivity of contraction upon increased sarcomere length,
i.e., the strength of any weak segments that undergo stretch
is increased, counteracting excessive sarcomere redistributions.
It was suggested that the lost capacity to respond to increased
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FIGURE 2 | Major elements of proposed hypothesis for development of HCM and related diseases in skeletal muscle. The enhancement of certain
effects by specific elements is indicated by plus signs. Details are considered in the text.
filling pressure in HCM in the case of a blunted Frank-Starling
mechanism might, in itself, initiate compensatory hypertrophy
(Sequeira et al., 2013). On the other hand, the phenomenon
would clearly also contribute to the mechanism proposed here
and it may be important in pathogenesis if the Frank-Starling
mechanism is blunted not only in HCM patients but also in
healthy mutation carriers. As mentioned above, a range of
HCM mutations cause rather subtle changes in the kinetics and
mechanical properties of the actomyosin cross-bridges. In order
to investigate whether such effects may cause instabilities in
the F-V relationship, as described above, we performed a num-
ber of simulations using a model developed from recent work
(Albet-Torres et al., 2009; Mansson, 2010; Persson et al., 2013)
(Supporting Information). First, we found that isolated changes
in only a limited number of the parameter values (Tables S1, S2)
could reproduce instabilities in the F-V curve of the type illus-
trated in Figure 3, with only small simultaneous changes in
maximal tension and maximal velocity, typically seen in HCM.
Of particular interest in this connection was an isolated increase
(∼40%) in cross-bridge stiffness that causes an anomalous F-
V relationship (red, Figure 3A) with regions of positive slope
and the mentioned type of instability with more than one sta-
ble velocity for a given load. This effect is due to the fact that
the cross-bridge, after attachment, has to overcome an increased
free-energy barrier (Figure S1), as result of increased stiffness, in
stretching the elastic element before entering into the main force-
generating state. This energy barrier is lowered by the reduced
cross-bridge strain during shortening which explains why force
can be as high or higher during slow shortening (red, Figure 3A)
than in isometric contraction.
NON-UNIFORMITY BETWEEN CARDIAC MUSCLE CELLS OR ALONG
SKELETAL MUSCLE FIBERS
Non-uniformity in strength of contraction between different car-
diac muscle cells in series or along a skeletal muscle fiber, for
whatever reason, will inevitably lead to shortening and elongation
of the strongest and weakest segments, respectively if the muscle
as a whole undergoes isometric contraction. The phenomenon
exists physiologically along skeletal muscle fibers where it has
been studied in appreciable detail (Gordon et al., 1966; Julian and
Morgan, 1979; Edman and Reggiani, 1984; Edman et al., 1985,
1988). It has also been studied in mammalian myofibrils from
heart and skeletal muscle (Stehle et al., 2002; Poggesi et al., 2005).
Furthermore, two populations of cells differing with respect to
certain contractile properties have been observed among porcine
cardiomyocytes (McDonald et al., 2012).
The non-uniformity in contractile properties between dif-
ferent cardiac myocytes and along a skeletal muscle fiber has
important physiological roles. This includes effects to speed up
relaxation after an isometric contraction (Edman and Flitney,
1982; Poggesi et al., 2005) and to contribute to some aspects of
the resistance to stretch (Campbell et al., 2011; Edman, 2012;
Rassier, 2012). However, excessive stretch of some muscle seg-
ments associated with non-uniformities may also be the basis of
cellular damage (Macpherson et al., 1997).
Interestingly, increased variability in calcium sensitivity
(reported as pCa) was observed (Kirschner et al., 2005) between
different skeletal muscle fibers of a given patient either affected
by an Arg723Gly, Arg719Trp, or an Ile736Thr mutation in the
β-cardiac/slow myosin gene (MYH7). In the discussion they
(Kirschner et al., 2005) stated: “the variability in pCa(50) from
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FIGURE 3 | Simulated relationship between force and shortening
(positive) and lengthening velocity (negative). (A) Black symbols and
connecting lines: standard parameter values (Table S1; corresponding to
normal healthy fast skeletal muscle). Red symbols and connecting lines:
standard parameter values but cross-bridge stiffness increased by 40%
without further changes in parameter values. Inset: simulated force-velocity
data in the high force region shown in greater detail. (B) The force-velocity
relationship for the standard conditions in (A) re-plotted together with
simulated lengthening part of the relationship either assuming same
attachment rate as during shortening and isometric contraction (Equation
S4a; black symbols) or assuming increased attachment rate with increased
velocity of lengthening (Equation S4b; blue symbols). The latter data are
reasonably consistent with experimental data (Lombardi and Piazzesi, 1990)
whereas the former are not.
fiber to fiber is likely to cause imbalances in force generation and
be the primary cause for contractile dysfunction and development
of disarray in the myocardium.”
One factor contributing to non-uniform contractile prop-
erties between different muscle segments under physiological
conditions is differential expression of different myosin isoforms.
For instance, different myosin isoform composition has been
observed along the length of individual skeletal muscle fibers
associated with the protein expression control by different nuclei
of these multinuclear cells (Edman et al., 1988; Rosser and
Bandman, 2003).
Related to this observation, Kirschner et al. (2005) also con-
sidered whether the non-uniformities in pCa between cells may
be attributed to different content of mutated protein. Such effects
may occur in heterozygous individuals with HCM if there is dif-
ferent fractional expression of mutated and wild-type protein in
different cardiac cells or along a given skeletal muscle fiber (as
used by Kirschner et al., 2005). However, it is not straightforward
to reconcile the idea with findings (Fatkin et al., 1999; Ho et al.,
2000; Richard et al., 2000; Nanni et al., 2003) that patients and
experimental animals, who are homozygous for a given mutation,
exhibit a more severe phenotype than those who are heterozy-
gous. This finding suggests that the amount of mutated protein
per se, is the critical factor. This idea is also consistent with pos-
itive correlation (Casadonte et al., 2006; Tripathi et al., 2011; Di
Domenico et al., 2012) between the phenotype severity and the
fractional expression of mutated protein in heterozygous indi-
viduals, although other interpretations (Tripathi et al., 2011)
are possible. The increased severity with increased fraction of
mutated protein also seems to accord with recent findings that
RNA interference based inhibition of the expression of mutated
myosin prevents development of HCM upon just 25% reduction
in the level of the mutant transcripts (Jiang et al., 2013).
Of course, in spite of the above findings, one cannot exclude
the possibility that non-uniform expression of mutated and wild-
type myosin in different cells may affect disease severity in het-
erozygous individuals or that the pathogenic mechanisms differ
between the homozygous and heterozygous cases. However, if it
will be possible to conclusively demonstrate that the effect of non-
uniform expression is negligible and that it is the overall amount
of mutated protein that is important, the findings of Kirschner
et al. (Kirschner et al., 2005) of inter-cellular variability must be
explained by another mechanism. One may here consider overall
changes in cytoarchitecture that give variations in force between
cells or between cell segments, consistent with a developmental
origin (Olivotto et al., 2009). Another, basis for the effect may
be related to the myofibrillar disarray observed upon incorpo-
ration of myosin with HCM mutations into embryonic chicken
myocytes (Wang et al., 2003), or upon drug induced (instead
of mutation induced) modifications of contraction kinetics of
embryonic myocytes (Rodriguez et al., 2013). Similar myofibrillar
disarray in human cardiomyocytes during embryonic develop-
ment in the presence of HCMmutationsmay account for the vari-
ability if different cells or cell segments are affected by disarray to
different degree. Irrespective of the reason for variability between
cells, the weakest cells or cell segments will be stretched by the
remaining cells during isovolumetric/isometric contraction, an
effect that might be worsened by changes to the load-velocity rela-
tionship as indicated in Figure 3. Such stretch would be sensed by
tension-, and strain-sensing systems in the sarcomeres (Luther,
2009; Linke and Kruger, 2010; Ottenheijm et al., 2011) (see above)
and elsewhere, e.g., in the cell membrane (Bernardo et al., 2010)
with initiation of hypertrophic signaling. Areas with mechanical
non-uniformity and local activation of such signaling pathways
may then function as foci from which areas of hypertrophy, fibro-
sis and disarray on the myocyte level spread (Figure 2). This
course of events is consistent with focal areas of abnormal strain
and fibrosis seen within the limited resolution of cardiac imag-
ing in patients with fully developed HCM (Nagakura et al., 2007;
Ghio et al., 2009; Maron et al., 2009). Of even greater interest,
regional and patchy irregularities in morphology (Germans et al.,
2006) (without hypertrophy) and ventricular wall strain during
both systole and diastole have also been observed (Cardim et al.,
2002; Yiu et al., 2012; Forsey et al., 2013) in mutation carriers.
These changes have particularly been seen in those regions of the
ventricle where hypertrophy and fibrosis is most severe late in the
course of the disease.
A simplified model (Supplementary Material) was used in
order to elucidate the effect of non-uniform contractile proper-
ties between cardiac myocytes (∼100μm long) in series or along
several cm long skeletal muscle fibers. Here we approximated
this complex arrangement by assuming that two sarcomeres with
different contractile properties act in series.
Figure 4 illustrates the effect of different force-generating
capacity of the two sarcomeres (corresponding to cells or cell-
segments) in series and the effect under these conditions of
instability in the F-V relationship (red symbols in Figure 3). In
Figure 4A, the tension and length changes of the two cells were
simulated assuming that one of the sarcomeres develops 30%
higher maximum force than the other, e.g., corresponding to
www.frontiersin.org September 2014 | Volume 5 | Article 350 | 5
Månsson Mechanical instabilities in myopathies
FIGURE 4 | The effect of different force-generating capacity or calcium
sensitivity of two cells in series on simulated tension and length
response. (A) Effect of 30% higher maximum tension of one cell. Force
clamped to 70% of maximum isometric force of weaker cell. Full lines:
Force-velocity curve as black symbols in Figure 3. Dashed lines:
Force-velocity curve as red symbols in Figure 3. Blue: response of cell with
lowest tension-generating capacity. Red: response of strongest cell. Black
in length-time plot: sum of length change for both cells in series. (B) Similar
to (A), but only 10% higher maximum tension of one cell and force
clamped to 85% of maximum isometric force of weaker cell. Line formats
and color codes as in (A). Full calcium activation assumed from onset of
simulation. (C) Simulated time course including activation process with
higher calcium sensitivity of contractile system in one cell (red) but similar
maximum isometric tension in both cells. Line formats as in other panels.
(D) Dashed lines, same as dashed lines in (C). Dotted lines, same as in
(C) but velocity-dependent increase in attachment rate during stretch as
described in text.
more myofibrils in parallel or more correctly oriented myofibrils
on the cellular level. The results are shown for both cases with a
stable (black line in Figure 3) and instable (red line in Figure 3) F-
V relationship of both sarcomeres. In Figure 4B similar results are
shown as in Figure 4A but with only 10% higher force develop-
ment of one sarcomere compared to the other, and with clamping
of the force to 85% (instead of 70% in Figure 4A) of the maxi-
mum isometric force of the weakest sarcomere. It can be seen in
both Figures 4A,B that the stronger sarcomere shortens, stretch-
ing the sarcomere in series during the overall isometric phase of
contraction. It can also be seen that this effect is enhanced with
the anomalous F-V curve (red curve in Figure 3), particularly
when the load is clamped to the higher level and when the differ-
ence in maximum force-generating capacity is small (Figure 4B).
Effects of calcium-activation are included in the simulations
in Figure 4C, for cases with a stable (black line in Figure 3)
and instable (red line in Figure 3) F-V relationship. As expected,
the sarcomere with highest calcium-sensitivity shortens during
the isometric phase (corresponding to isovolumetric phase in the
heart), stretching the sarcomere in series, in spite of the same
maximum isometric tension in the two sarcomeres. Here, the
instability of the F-V relationship only had a small enhancing
effect on the amount of stretch of the weak sarcomere during
the overall isometric phase of the contraction. This may be due
to reduced instability at low level of activation, due to assumed
calcium dependence of the attachment rate constant in these sim-
ulations. Importantly, not all models of activation include this
assumption (Cecchi et al., 1981).
In the simulations above, it was assumed that the rate of
myosin head attachment was not increased by stretch. If, instead,
the attachment rate was assumed to increase with lengthening
velocity, a type of effect found necessary in previous mod-
els (Lombardi and Piazzesi, 1990; Mansson, 2010) (see also
Figure 3), the sarcomere length redistribution was reduced in
amplitude as illustrated in Figure 4D.
IMPLICATIONS, LIMITATIONS, AND POTENTIALS OF MODEL
STUDIES
The present model-simulations merely aim to illustrate the type
of effects that may be seen due to sarcomere instabilities and non-
uniform contractile properties between myocardial cells, or along
a skeletal muscle fiber rather than simulating the exact behav-
ior of human muscle. This limitation in scope is largely due to
the limited availability of experimental data for full definition
of the models under physiological conditions. This particularly
applies to human cardiac muscle but also to an appreciable extent
to mammalians skeletal muscle (Supporting Information). Thus,
whereas model studies at present have certain limitations, on-
going developments are likely to increase their usefulness. In
particular, kinetic and elastic properties of both wild-type and
mutated cardiac myosins are in the process of being elucidated in
similar detail to fast skeletal muscle myosin (Deacon et al., 2012;
Bloemink et al., 2013; Sommese et al., 2013b). Similar develop-
ments are underway (Bai et al., 2013) for the contractile effects of
e.g., regulatory thin filament proteins.
Clearly, to refine the model in order to critically evaluate the
current idea that some sarcomeres are stretched by others, it will
be essential to increase of the understanding of the lengthening
part of the load-velocity relationship and establish whether car-
diomyopathy mutations might affect this part (cf. Figures 4C,D).
Better models based on more complete experimental data
should give further insights into the effect of the myopathy
mutations in otherwise normal cells, before they are affected by
remodeling. The models would allow extrapolation from single
molecule results to ensemble function and also allow the incor-
poration of effects on higher level of hierarchial organization than
that of sarcomeres and half-sarcomeres.
SUGGESTED EXPERIMENTAL TESTS
In studies of cardiomyopathies, using isolated proteins, limited
effort has, so far, been devoted to the detailed shape of the load-
velocity relationship for shortening as well as lengthening. Studies
of F-V data have mainly utilized semi-quantitative methods with
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so called loaded motility assays, where actin-binding proteins
impose a frictional load between the surface and actin filaments
(Bing et al., 2000; Sommese et al., 2013b). Whereas this technique
detects gross changes in maximum power output it seems less
likely that it will detect more subtle changes in shape of the force
velocity relationship such as exemplified in Figure 3. In order to
detect the types of instabilities considered here, high-resolution
studies will be required to obtain F-V data from small ensembles
of contractile proteins. The use of small ensembles is important
because the F-V relationship is a property of an ensemble of acto-
myosin motors (Huxley, 1957; Eisenberg and Hill, 1978; Vilfan
et al., 1999).
An interesting question, in terms of non-uniformities between
cardiomyocuytes, is whether there is allelic expression of myosin
so that some cells express the wild type and some the mutant
or whether there is variable expression of both within one cell
(Kirschner et al., 2005). However, whatever the cause of non-
uniformities between cells, it is clear from the simulations that
they would lead to increased lengthening of some cells and
shortening of others during overall isovolumetric/isometric con-
traction. One would thus expect increased non-uniformity in
strain during systole in the whole heart of healthy human muta-
tion carriers, (cf. Ghio et al., 2009). Further insight in this regard
relies on further improvements of methods for cardiac imaging.
Increased non-uniformity of sarcomere behavior during contrac-
tion should also be possible to detect in cardiac ventricular strips
from experimental animals and between segments along a skeletal
muscle fiber. Another interesting test would be if a given degree of
expression of a mutated myosin in e.g., a transfected embryonic
cardiomyocyte (Wang et al., 2003) leads to increased variability
in the degree of myofibrillar disarray indicating the possibility of
non-uniformities developing embryologically.
Onemay also consider attempts to probe how activation of sig-
nal transduction systems is spatially and temporally distributed
over the cardiac ventricle in experimental animals with HCM
causing mutations. Finally, it may be of interest to consider the
option to control the process in greater detail by actually induc-
ing local non-uniformities in contractile function in situ, perhaps
by localized adeno-associated virus (AAV) based transfection of
relevant genes. The animals should then be followed up with
regard to the presence of non-uniform contraction, localized
AT-II signaling and, finally, development of a HCM phenotype.
SKELETAL MUSCLE MYOPATHIES
Skeletal muscle sarcomere myopathies are due to mutations in
similar genes as cardiomyopathies but the mutations that pre-
dominantly cause severe disease differ. Whereas myosin and
myosin-binding protein C are mainly affected in HCM (see
above) it is mainly thin filament proteins such as nebulin
(not present in heart), actin, tropomyosin, troponin T and
troponin I that are affected in severe sarcomere myopathies
in skeletal muscle (Laing, 2007; Ochala, 2008). It is particu-
larly puzzling that that even malignant HCM-mutations e.g.,
in the MYH7 gene, with modified ventricular β-myosin heavy
chain, identical to the slow skeletal muscle myosin heavy chain,
often give a mild skeletal muscle phenotype (Oldfors, 2007).
One may speculate about reasons for this, from differences
in signaling cascades that are activated by the mutation over
different loading conditions of the different muscles to dif-
ferent compensatory mechanisms, i.e., involving altered state
of phosphorylation of a range of regulatory proteins in the
heart and compensatory use of non-slow motor units in skele-
tal muscle. These are interesting questions that may teach us
lessons about the pathogenesis but they are not a major focus
here.
The most common among the rare skeletal muscle sarcomere
myopathies with bewildering morphological and clinical conse-
quences are denoted nemaline myopathy and distal arthrogrypo-
sis. These are caused by a range of mutations in the thin filament
proteins. The nemaline myopathies, in addition to being charac-
terized by specific morphological changes late in the course of the
disease, with so called nemaline bodies (Ochala, 2008), contain-
ing actin and sarcomere Z-line proteins seem to exhibit reduced
Ca-sensitivity and hypocontractility (Ochala, 2008; Ochala et al.,
2012; Memo and Marston, 2013). In contrast, distal arthrogry-
oposis is characterized by increased Ca-sensitivity and hyper-
contractility (Robinson et al., 2007; Ochala, 2008; Memo and
Marston, 2013), e.g., with contractures in distal muscles. For
other skeletal muscle diseases, the reader is referred to a num-
ber of comprehensive recent reviews (Laing and Nowak, 2005a;
Laing, 2007; Oldfors, 2007; Ochala, 2008; Wallgren-Pettersson
et al., 2011; Tajsharghi and Oldfors, 2013).
In spite of the differences from cardiomyopathies, I postulate
that the basic mechanisms for muscle destruction in several skele-
tal muscle diseases, caused by mutations in sarcomere proteins,
are similar to the hypertrophy response in heart, i.e., instabili-
ties on the sarcomere level and non-uniformities along the length
of the muscle. This is consistent with the fact that the results of
Kirschner et al. (2005), on basis of which they proposed that non-
uniformities are important in cardiomyopathies, were actually
derived using slow skeletal muscle preparations.
If there are increased differences in force-generating capability
along skeletal muscle fibers with sarcomere myopathy mutations
one would expect increased sarcomere re-distributions within the
fiber with the risk that some segments are overstretched (see
above for mechanisms). In skeletal muscle fibers it is also known
that stretch could stimulate hypertrophy (Roig et al., 2009). On
the other hand, extensive non-uniform stretch, possibly facilitated
by instabilities of the F-V relationship may lead to cell dam-
age. Indeed, cell damage, rather than hypertrophy may be even
more likely in skeletal muscle than in the heart as the Frank-
Starling mechanism, giving increased Ca-sensitivity with stretch,
may counteract the stretch in heart muscle but is not present in
skeletal muscle.
CONCLUSIONS
The present paper has analyzed a hypothesis according to which
the early compensatory changes in HCM occur due to local
stimulation of cell-signaling mechanisms similar to those in
pressure-overload. According to this hypothesis, locally increased
mechanical stress on the cardiomyocytes is of key importance as
an initiating factor and may be brought about by one or both of
two different mechanisms: (1) contractile instabilities within each
sarcomere (with more than one stable velocity for a given load)
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under certain loading conditions and (2) non-uniform mechan-
ical properties (strength) of different cells leading to a tendency
for inhomogeneous stretch of certain regions of the ventricle wall
during parts of the cardiac cycle.
One common denominator of the proposed mechanisms is
that they are not readily detected in studies using conventional
preparations such as isolated proteins or cells already affected
by secondary compensatory changes. What is required, in gen-
eral, are studies on higher organizational levels using cells,
tissues, whole hearts or sarcomere like ensembles that con-
tain mutated proteins but that are unaffected by compensatory
changes. Furthermore, for any form of mechanical studies to
detect the ensemble effects it will be critical to explore the range of
loads experienced during the cardiac cycle. The hypothesis, with
slight modifications, may also be relevant in the pathogenesis of
skeletal muscle myopathies.
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